secwatch.observer — SEC 8-K summary
======================================

Issuer:     Instil Bio, Inc. (TIL)
CIK:        0001789769
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001789769-24-000082
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Instil Bio Q2 net loss $2.29/share; in-licenses two assets, leases facility to AstraZeneca
--------------------------------------------------------------------------------

- Net loss per share $2.29 (GAAP), non-GAAP $1.57 for Q2 2024; improved from $2.87 and $2.03 in Q2 2023.
- Cash, equivalents, marketable securities and long-term investments $152.6M as of June 30, expected runway beyond 2026.
- In-licensed SYN-2510 (PD-L1xVEGF bispecific) and SYN-27M (ADCC-enhanced anti-CTLA-4) from ImmuneOnco for exclusive global rights outside Greater China.
- Executed 15-year lease of cell therapy manufacturing facility to AstraZeneca; initial base rent >$7.5M annually escalating at 3%.
- R&D expenses fell to $2.9M in Q2 2024 from $8.5M in Q2 2023; restructuring and impairment charges minimal.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789769/000178976924000082/0001789769-24-000082-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789769/000178976924000082/til-20240813.htm
  HTML page:      https://secwatch.observer/filing/0001789769-24-000082

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer